Search trials – HealthDB

AI · diabetes

Намерени 206 изпитвания за "diabetes" Стр. 9 от 11

Active (not recruiting)

The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes

Diabetes Mellitus

To assess the efficacy of the REST model in facilitating adoption and sustained use of CGM, in older adults with Type 1 diabetes (T1D) or Type 2 Diabetes (T2D) on complex insulin regimens. To examine barriers and enablers for the implementation feasibility of the REST intervention model using a mixed-methods approach. To assess the impact of REST model on economic factors and quality of life measures. The goal of this study is to facilitate the adoption of continuous glucose monitoring (CGM) in older adults (≥65 years) with diabetes mellitus (DM) on complex insulin regimens, and additionally, to build a framework for sustained CGM use over time using a novel patient-centered model - the REST model.

Начало: 20.04.2022 Край: 01.05.2026 Възраст: от 65 г.

United States Joslin Diabetes Center NCT05337826

Active (not recruiting) Phase 3

I4V-MC-JAJJ: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to

Diabetes Mellitus Type 1

Trial status: Authorised Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes [Time Frame: Baseline up to approximately 5 years]

Начало: 23.12.2025 Възраст: 18–64 г.

Belgium, Finland, France +8 Eli Lilly & Co. 2025-521797-34-00

Active (not recruiting) Phase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Overweight Obesity Type 2 Diabetes

This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.

Начало: 05.11.2025 Край: 30.06.2027 Възраст: от 18 г.

Argentina, Canada, Croatia +8 Novo Nordisk A/S NCT07220759

Active (not recruiting) Phase 1

Effect of Rosmarinus Officinalis Extract on Oxidative Stress and Inflammatory Biomarkers in Patients With Type 2 Diabetes(T2DM)

Type 2 Diabetes Mellitus (T2DM) Oxidative Stress Inflammation Chronic

This study will evaluate the effects of Rosmarinus officinalis (rosemary) extract on oxidative stress and inflammation in patients with type 2 diabetes. Participants will be randomly assigned to receive either rosemary extract or a placebo for 12 weeks. The study aims to determine whether rosemary extract can improve health markers related to oxidative stress, inflammation, and metabolic function.

Начало: 20.09.2025 Край: 17.08.2026 Възраст: от 18 г.

Mexico Universidad Autonoma de Zacatecas NCT07541729

Active (not recruiting)

Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes

Diabetes Mellitus

The purpose of the study is to assess the safety and efficacy of a next generation automated insulin delivery algorithm in adults with type 2 diabetes aged 16-70 years old

Начало: 01.07.2025 Край: 01.05.2026 Възраст: 16–70 г. Treatment

New Zealand Insulet Corporation NCT07039981

Active (not recruiting) Phase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity Overweight Type 2 Diabetes

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.

Начало: 19.05.2025 Край: 01.08.2027 Възраст: от 18 г.

Argentina, China, Czechia +4 Eli Lilly and Company NCT06972472

Active (not recruiting) Phase 2

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Type 1 Diabetes Mellitus

This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell function in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) on insulin therapy. The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into brivekimig and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo). The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.

Начало: 28.02.2025 Край: 29.04.2027 Възраст: 12–35 г. Treatment

Argentina, Australia, Brazil +5 Sanofi NCT06812988

Active (not recruiting) Phase 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese Type 2 Diabetes Mellitus (T2DM)

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Начало: 21.11.2024 Край: 24.09.2026 Възраст: 18–75 г. Treatment

Argentina, Canada, Mexico +3 Carmot Therapeutics, Inc. NCT06628362

Active (not recruiting) Phase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Diabetes Mellitus, Type 2

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

Начало: 05.11.2024 Край: 14.07.2026 Възраст: от 18 г. Treatment

Argentina, Australia, Brazil +11 Novo Nordisk A/S NCT06534411

Active (not recruiting)

At-Home Exercise Study for Veterans With Healed Diabetic Foot Ulcers

Diabetic Foot Ulcer

Foot ulcers and amputations are a common and feared complication for people with diabetes. People with a diabetic foot ulcer have a higher risk of dying within five years than people with diabetes without an ulcer. At least one in four people with a new diabetic foot ulcer will die within five years, largely due to cardiovascular causes. The reasons for this increased mortality involve decreased mobility. People with a recently healed diabetic foot ulcer are considered "in remission" as opposed to "cured" because the underlying medical problems which led to their ulcer are still present. Once in remission, the current standard of care is to slowly increase ambulation. The problem is that people rarely return to the recommended level of mobility. The ability to safely maintain mobility with aging is critical. This pilot study is a small clinical trial to test the feasibility and acceptability of a home-based exercise regimen. The investigators will also assess if this home-based exercise regimen can increase mobility and function without increasing diabetic foot ulcer recurrence by improving lower extremity strength, lower extremity tissue perfusion and glycemic control.

Начало: 01.10.2024 Край: 31.03.2027 Възраст: от 50 г.

United States VA Office of Research and Development NCT06312579

Active (not recruiting) Phase 2

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

Diabetes Mellitus, Type 1 Autoimmune Diseases Prevention

A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) also known as retogatein in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2 haplotype.

Начало: 09.07.2024 Край: 31.03.2028 Възраст: 8–18 г.

Sweden Diamyd Medical AB NCT05683990

Active (not recruiting) Phase 2

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Diabetes Mellitus, Type 1

A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.

Начало: 19.10.2023 Край: 30.06.2027 Възраст: 12–35 г. Treatment

Australia, Canada, United States National Institute of Diabetes and Digestive and Kidney NCT05743244

Active (not recruiting) Phase 3

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Type 2 Diabetes Obesity Overweight Obstructive Sleep Apnea

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Начало: 11.07.2023 Край: 01.05.2026 Възраст: от 18 г. Treatment

Argentina, Australia, Brazil +5 Eli Lilly and Company NCT05929079

Active (not recruiting)

Effectiveness of a Combined mHealth-CBT Psychological Intervention to Improve Psychological Well-Being in Young Patients With T1D

Diabetes Mellitus, Type 1

Type 1 diabetes (T1D) can lead to psychological adjustments that impact the acceptance and management of this health condition, as well as the overall quality of life of patients, especially among the young. Therefore, there is a need for psychological interventions aimed at enhancing the psychological well-being of children and adolescents with T1D. The goal of this non-randomized controlled trial is to evaluate whether a combined intervention comprising mHealth (using an app) and face-to-face psychological sessions based on Barlow's protocol and cognitive-behavioral therapy techniques (CBT) is effective in enhancing psychological well-being in children and adolescents with T1D. The main hypotheses are: * H1: The primary results expected to be obtained are a significant increase in psychological well-being, which means a decreased diabetes distress (DDS) (H1a) an increased subjective well-being (PANAS) (H1b) and a better self-efficacy for managing their emotions (RESE) (H1c). * H2: As secondary outcomes, it is also expected that the combined mHealth-CBT intervention would increase the level of positivity (P-Scale) (H2a), the self-esteem (RSES) (H2b) and the satisfaction with life (SWLS) (H2c).

Начало: 11.02.2023 Край: 01.09.2026 Възраст: 6–18 г.

Spain Maimónides Biomedical Research Institute of Córdoba NCT06450730

Active (not recruiting) Phase 1

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Diabetes Mellitus, Type 1

The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a therapeutic option for T1D patients and potentially other autoimmune disorders.

Начало: 27.02.2020 Край: 30.05.2027 Възраст: 18–40 г.

United States Medical University of South Carolina NCT04061746

Active (not recruiting) Phase 3

The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

Type 1 Diabetes Mellitus Diabetic Retinopathy Diabetic Nephropathies

The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative diabetic retinopathy.

Начало: 03.11.2016 Край: 01.12.2026 Възраст: от 18 г. Treatment

Australia, Hong Kong, New Zealand +1 University of Sydney NCT01320345

Active (not recruiting) Phase 2

Improving the Treatment for Women With Early Stage Cancer of the Uterus

Complex Endometrial Hyperplasia With Atypia Grade 1 Endometrial Endometrioid Adenocarcinoma

Currently the standard treatment for early stage endometrial cancer or endometrial hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and removal of both ovaries. While highly effective, this surgery carries significant side effects for: * young women who still wish to have children and would lose fertility; and * women with one or more disorders (or diseases) in addition to the early stage endometrial cancer or endometrial hyperplasia with atypia and/or morbid obesity who are at risk for surgical complications making surgery unsafe. This study will access a new approach to the treatment of endometrial cancer to spare women of having to undergo major surgery that may be unwanted or unnecessary. Mirena is approved in Australia for contraception, to treat heavy bleeding, and to prevent thickening of the lining of the uterus (endometrial hyperplasia) during oestrogen replacement therapy (HRT). However it is not approved to treat early stage endometrial cancer or endometrial hyperplasia with atypia. This research project will test to see if Mirena is an effective treatment for early stage endometrial cancer and endometrial hyperplasia with atypia. Metformin is approved in Australia to treat Diabetes. However it is not approved to treat early stage endometrial cancer or endometrial hyperplasia with atypia. Therefore, it is an experimental treatment for early stage endometrial cancer and endometrial hyperplasia with atypia. This means that it must be tested to see if it is an effective treatment for early stage endometrial cancer and endometrial hyperplasia with atypia. Weight loss interventions are feasible and safe, and already being implemented by gynaecologic oncologist to make women eligible for surgery. Weight loss of 7% body weight induces a large biological effect (for example reduces incidence of diabetes by 58%, and hypertension by 26%).

Начало: 01.12.2012 Край: 01.12.2026 Възраст: от 18 г. Treatment

Australia, New Zealand Queensland Centre for Gynaecological Cancer NCT01686126

Active (not recruiting) Phase 4

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

Chronic Kidney Diseases Type 2 Diabetes

The purpose of this study is to determine if starting all four chronic kidney disease therapies at the same time is safe and effective in patients with Type 2 Diabetes and Chronic Kidney Disease. Study hypothesis states that starting all four recommended kidney medications at the same time is safe and effective in reducing albuminuria, a protein in the urine, without a decline in kidney function or increase in potassium levels compared to starting one medication at a time.

Начало: 09.04.2026 Край: 31.03.2029 Възраст: 18–84 г.

United States Baylor Research Institute NCT07547878

Active (not recruiting)

Neural Mobilization vs Cervical Neuromodulation in DPN

Diabetic Peripheral Neuropathy Type 2

This study is a three-arm, assessor-blinded, randomized controlled pilot feasibility trial. The primary goal is to evaluate the feasibility and acceptability of conducting a full-scale randomized controlled trial (RCT) comparing two manual therapy techniques: Manual Neural Mobilization (MNM) and Cervical Neuromodulatory Intervention (CNI) in individuals with Diabetic Peripheral Neuropathy (DPN). While glycemic control is a central part of managing type 2 diabetes, this study explores whether non-pharmacological manual therapies can serve as adjunctive interventions to improve metabolic outcomes. A total of 75 participants were assigned to either MNM, CNI, or standard care for 12 weeks. The study focuses on recruitment rates, adherence, and safety, while also exploring secondary outcomes like blood glucose levels (HbA1c, FBG) and pain intensity.

Начало: 05.02.2026 Край: 01.06.2026 Възраст: 18–65 г.

Egypt Abeer Abdrabo NCT07537270

Active (not recruiting) Phase 3

I4V-MC-JAJK: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to

Diabetes Mellitus Type 1

Trial status: Authorised Change from Baseline in C-peptide Area Under the Curve (AUC) [Time Frame: Baseline, Week 52]

Начало: 02.02.2026 Възраст: 18–64 г.

Belgium, Czech Republic, Finland +9 Eli Lilly & Co. 2025-522170-36-00

1 … 7 8 9 10 11